Wilmington Savings Fund Society FSB Trims Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Wilmington Savings Fund Society FSB cut its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 93.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,759 shares of the company’s stock after selling 36,814 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Teva Pharmaceutical Industries were worth $56,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. purchased a new stake in Teva Pharmaceutical Industries in the 2nd quarter worth about $41,000. Cromwell Holdings LLC grew its stake in shares of Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after buying an additional 629 shares during the last quarter. Sound Income Strategies LLC raised its holdings in shares of Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after buying an additional 2,824 shares during the period. MAI Capital Management raised its holdings in shares of Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after buying an additional 697 shares during the period. Finally, JTC Employer Solutions Trustee Ltd bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $65,000. 54.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, VP Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the transaction, the vice president directly owned 48,384 shares in the company, valued at approximately $1,387,653.12. This trade represents a 70.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Amir Weiss sold 12,300 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the transaction, the chief accounting officer directly owned 5,650 shares of the company’s stock, valued at approximately $170,630. The trade was a 68.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 622,060 shares of company stock valued at $17,076,965. 0.49% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Trading Up 0.8%

NYSE:TEVA opened at $31.66 on Friday. The firm has a 50-day simple moving average of $29.51 and a 200-day simple moving average of $22.48. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $33.42. The firm has a market cap of $36.31 billion, a P/E ratio of 52.77, a P/E/G ratio of 1.80 and a beta of 0.66. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11.

Analysts Set New Price Targets

TEVA has been the topic of several research analyst reports. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Sunday, January 18th. Scotiabank started coverage on shares of Teva Pharmaceutical Industries in a report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price target on the stock. Jefferies Financial Group raised their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Finally, The Goldman Sachs Group boosted their price objective on shares of Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $33.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.